CVRx went public in June 2021, raising approximately $126 million in an IPO. Read here to learn more about the CVRX stock and the IPO.

Helius Medical Technologies (Nasdaq:HSDT) announced today that it priced a public offering of common stock worth $18 million. Newtown, Pennsylvania-based Helius, which develops the PoNS (portable neuromodulation stimulator), is offering 24 million shares of Class A common stock and warrants to purchase up to 36 million shares of Class A common stock at a purchase […]

Colonial Oil Industries — based in Savannah, Ga. — has hired Bob Kenyon to serve in the position of division president. “Bob has the expertise and knowledge of the industry to lead COI into the future,” said Christian Demere, Colonial Group president and CEO. “More importantly, he has the leadership skills to develop and build…

Advanced Energy Industries, Inc. expands its presence in the industrial, robotics, and 5G telecom markets with the launch of the AE Artesyn AIF42 AC/DC converter. The new converter reduces system size, delivers best-in-class 93% efficiency, and enhances reliability by minimizing the need for external components. The AIF42 full brick module is rated for 500 W […]

The upgraded clubhouse at the Naples, Fla. facility will have new men’s and women’s locker rooms, a new fitness studio, two golf course simulators, a private dining room, a player’s lounge with a bar, indoor and outdoor seating, new bathrooms, a banquet kitchen, an office for the food and beverage manager, and a golf shop…

Bourns, Inc. announced the industry’s first Power Transient Voltage Suppressor (PTVS) product families available in the compact DFN package (8 mm x 6 mm x 2.5 mm) The Bourns PTVS1 and PTVS2 surface mount series provide effective ESD protection to meet the growing demand for high surge current solutions that can also help designers save valuable PCB board space. […]

CVRx, Inc. (NASDAQ:NASDAQ:CVRX) Q2 2022 Earnings Conference Call July 28, 2022 05:30 p.m.

MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022. The Company is scheduled to present at 8:30 am Eastern Time the same day via webcast.

https://www.investing.com/news/pro/cvrx-inc-pt-lowered-to-16-at-canaccord-genuity-432SI-2858118

CVRx press release (CVRX): Q2 GAAP EPS of -$0.54 misses by $0.01.Revenue of $5.03M (+61.2% Y/Y) beats by $0.33M.For the third quarter of 2022, the Company expects to report…

Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year

CVRx (NASDAQ: CVRX ) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here''s what investors need to know before the announcement. Analysts estimate that CVRx will report an earnings per share (EPS) of $-0.53. CVRx bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

Shares of micro-cap company CVRx (CVRX) rose as much as 11.7% to $7.57 in Monday trading, after Craig-Hallum research initiated the medical device firm with a buy…

The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which

The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support

CVRx Inc. (NASDAQ:CVRX) traded at $7.02 at close of the session on Friday, 06/24/22, made an upward move of 5.56% on its previous day’s price. Looking at the stock we see that its previous close was $6.65 with the day’s price range being $6.26 – $7.185. In terms of its 52-week price range, CVRX has … CVRx Inc. (NASDAQ: CVRX) Is On The Rise Read More »

CVRx''s (CVRX) Barostim is a long-term compounder that presents interesting economics. Read this article to check out what hurt CVRX stock price.

The trading price of CVRx Inc. (NASDAQ:CVRX) closed higher on Friday, June 17, closing at $5.62, 3.50% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $5.43 and … Attention Investors: What’s Really Going On With CVRx Inc. (NASDAQ: CVRX) Read More »